Tai Chi Group: Buprenorphine Tartrate Injection has received its drug registration certificate, with specifications of 1ml:1mg and 2ml:4mg.

Taiji Group Announcement: The company's holding subsidiary, Southwest Pharmaceutical, has received the "Drug Registration Certificate" for Buprenorphine Tartrate Injection issued by the National Medical Products Administration. The specifications for the drug are 1ml:1mg and 2ml:4mg, with a registration classification of Class 3 chemical drugs. The approval numbers are Guoyaozhunzi H20265615 and Guoyaozhunzi H20265616. This drug is classified as a Class II psychotropic drug and is suitable for the treatment of various cancer-related pain and postoperative pain. Southwest Pharmaceutical is the sixth company to obtain the production approval for this drug, with a total R&D investment of 9.2421 million yuan.